Company Sees FY26 Adjusted EBITDA of $680M-$730M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy AHCO?
Sees FY26 adjusted EBITDA $680M-$730M. Sees FY26 free cash flow $175M-$225M. The company said, "While fourth quarter 2025 Adjusted EBITDA was impacted by a legal settlement expense of $14.5 million and over $10 million of strategic investments to accelerate onboarding the new capitated contract, the underlying earnings power of the business remains intact."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AHCO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AHCO
Wall Street analysts forecast AHCO stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 9.150
Low
13.00
Averages
13.00
High
13.00
Current: 9.150
Low
13.00
Averages
13.00
High
13.00
About AHCO
AdaptHealth Corp. is a provider of patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. The Company provides a full suite of medical products and solutions designed to help patients manage chronic conditions in the home. Its product and service offerings include sleep therapy equipment, supplies, and related services (including CPAP and bi PAP services) to individuals suffering from obstructive sleep apnea; medical devices and supplies to patients for the treatment of diabetes, including continuous glucose monitors and insulin pumps; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home, and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy and nutritional supply needs. It operates in 50 states through its network of over 670 locations in 47 states.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Halper Sadeh Investigates AdaptHealth Board Responsibilities
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of AdaptHealth Corp. breached their fiduciary duties to shareholders, potentially impacting corporate governance and shareholder rights.
- Legal Relief Options: Long-term shareholders of AdaptHealth stock may seek corporate governance reforms, fund recovery, or court-approved financial awards, which could directly affect the company's financial health and shareholder value.
- Importance of Participation: Shareholder involvement can improve a company's policies, practices, and oversight mechanisms, enhancing transparency and accountability, ultimately increasing shareholder value and reflecting effective corporate governance.
- Global Investor Representation: Halper Sadeh LLC represents investors worldwide, focusing on combating securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors, demonstrating its influence in protecting investor rights.
See More
Wolverine World Wide Sees Surge in Options Trading Volume
- Surge in Options Volume: Wolverine World Wide (WWW) experienced an options trading volume of 11,306 contracts today, equating to approximately 1.1 million shares, which represents about 89.9% of its average daily trading volume over the past month, indicating strong market interest in its stock.
- High Put Option Activity: Notably, the $17.50 strike put option has seen significant trading, with 6,111 contracts exchanged today, representing around 611,100 shares, reflecting investor expectations of potential downward price movement.
- AdaptHealth Options Activity: Concurrently, AdaptHealth Corp (AHCO) also witnessed notable options trading, with a volume of 7,945 contracts, equivalent to approximately 794,500 shares, accounting for 82.8% of its average daily trading volume over the past month, highlighting active market engagement.
- Active Call Option Trading: The $10 strike call option for AHCO has been particularly active, with 7,847 contracts traded today, representing about 784,700 shares, suggesting a bullish sentiment among investors regarding its future stock price appreciation.
See More
Hospital and Medical Practitioners Stocks Decline
- Market Underperformance: On Tuesday, hospital and medical practitioners' stocks collectively fell by approximately 1.2%, indicating a decline in market confidence in the sector, which could negatively impact long-term investor expectations.
- AdaptHealth Leads Decline: AdaptHealth's stock plummeted by about 13.6%, making it the worst performer in the industry, suggesting potential operational or financial challenges that could affect its market share.
- Centene Pressured: Centene's stock decreased by approximately 3.5%, and although the drop is smaller, it still reflects market concerns regarding its future growth, potentially prompting investors to reassess their investment strategies.
- Industry Trend Warning: The overall decline in the healthcare sector may signal broader economic issues, prompting investors to monitor relevant policy changes and market dynamics to adjust their portfolios accordingly.
See More
AdaptHealth Reports Strong Q4 2025 Earnings and Strategic Growth
- Strong Financial Performance: AdaptHealth reported full-year revenue of $3.245 billion and Q4 revenue of $846.3 million, both exceeding the midpoint of guidance, indicating robust market performance and a solid financial foundation.
- Record Patient Census: The patient census in sleep health grew by 4% year-over-year, while new starts in respiratory health increased by 4% and 5%, respectively, enhancing the company's market share and competitive position in the rapidly evolving health management sector.
- Successful Strategic Transformation: The company executed the largest capitated contract in the industry, onboarding the Mid-Atlantic cohort smoothly, marking a significant shift in its business model that is expected to provide strong support for future revenue growth.
- Optimistic Future Outlook: Management anticipates revenue growth of 6% to 8% in 2026, with significant contributions from new agreements, demonstrating the company's commitment to optimizing operations and capital allocation aimed at achieving long-term sustainable growth.
See More
AdaptHealth Reports Q4 Earnings Beat Expectations
- Earnings Highlights: AdaptHealth reported a Q4 EPS of -$0.76, which may not be comparable to the consensus of $0.34; however, its revenue of $846.2 million, down 1.2% year-over-year, beat expectations by $14.6 million, demonstrating resilience amid challenges.
- Annual Guidance: The company provided FY26 net revenue guidance of $3.44 billion to $3.51 billion, aligning with the consensus of $3.44 billion, indicating management's confidence in future growth despite market headwinds.
- Adjusted EBITDA Outlook: Expected adjusted EBITDA is projected between $680 million and $730 million, reflecting ongoing efforts in cost control and operational efficiency aimed at enhancing profitability.
- Free Cash Flow Forecast: The anticipated free cash flow range of $175 million to $225 million will support future investments and debt repayments, thereby strengthening the company's financial flexibility.
See More
AdaptHealth to Release Q4 and Full Year 2025 Financial Results
- Earnings Release Schedule: AdaptHealth is set to announce its fourth quarter and full year 2025 financial results before the market opens on February 24, 2026, which is expected to provide investors with critical financial data and updates on business activities.
- Teleconference Details: Management will host a teleconference at 8:30 a.m. ET to discuss the financial results, with investors able to participate by dialing (833) 316-2483 (Domestic) or (785) 838-9284 (International), ensuring transparency of information.
- Webcast Replay Availability: Following the live call, a replay will be available for six months on the company's website under the 'Investor Relations' section, facilitating access for investors who could not attend in real-time and enhancing engagement with stakeholders.
- Business Overview: AdaptHealth is a leading provider of patient-centered healthcare-at-home solutions, serving approximately 4.3 million patients through a network of about 640 locations across 47 states, offering services in four key segments: Sleep Health, Respiratory Health, Diabetes Health, and Wellness at Home, demonstrating significant market influence.
See More
Halper Sadeh Investigates AdaptHealth Board Responsibilities
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of AdaptHealth Corp. breached their fiduciary duties to shareholders, potentially impacting corporate governance and shareholder rights.
- Legal Relief Options: Long-term shareholders of AdaptHealth stock may seek corporate governance reforms, fund recovery, or court-approved financial awards, which could directly affect the company's financial health and shareholder value.
- Importance of Participation: Shareholder involvement can improve a company's policies, practices, and oversight mechanisms, enhancing transparency and accountability, ultimately increasing shareholder value and reflecting effective corporate governance.
- Global Investor Representation: Halper Sadeh LLC represents investors worldwide, focusing on combating securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors, demonstrating its influence in protecting investor rights.
See More
Wolverine World Wide Sees Surge in Options Trading Volume
- Surge in Options Volume: Wolverine World Wide (WWW) experienced an options trading volume of 11,306 contracts today, equating to approximately 1.1 million shares, which represents about 89.9% of its average daily trading volume over the past month, indicating strong market interest in its stock.
- High Put Option Activity: Notably, the $17.50 strike put option has seen significant trading, with 6,111 contracts exchanged today, representing around 611,100 shares, reflecting investor expectations of potential downward price movement.
- AdaptHealth Options Activity: Concurrently, AdaptHealth Corp (AHCO) also witnessed notable options trading, with a volume of 7,945 contracts, equivalent to approximately 794,500 shares, accounting for 82.8% of its average daily trading volume over the past month, highlighting active market engagement.
- Active Call Option Trading: The $10 strike call option for AHCO has been particularly active, with 7,847 contracts traded today, representing about 784,700 shares, suggesting a bullish sentiment among investors regarding its future stock price appreciation.
See More
Hospital and Medical Practitioners Stocks Decline
- Market Underperformance: On Tuesday, hospital and medical practitioners' stocks collectively fell by approximately 1.2%, indicating a decline in market confidence in the sector, which could negatively impact long-term investor expectations.
- AdaptHealth Leads Decline: AdaptHealth's stock plummeted by about 13.6%, making it the worst performer in the industry, suggesting potential operational or financial challenges that could affect its market share.
- Centene Pressured: Centene's stock decreased by approximately 3.5%, and although the drop is smaller, it still reflects market concerns regarding its future growth, potentially prompting investors to reassess their investment strategies.
- Industry Trend Warning: The overall decline in the healthcare sector may signal broader economic issues, prompting investors to monitor relevant policy changes and market dynamics to adjust their portfolios accordingly.
See More
AdaptHealth Reports Strong Q4 2025 Earnings and Strategic Growth
- Strong Financial Performance: AdaptHealth reported full-year revenue of $3.245 billion and Q4 revenue of $846.3 million, both exceeding the midpoint of guidance, indicating robust market performance and a solid financial foundation.
- Record Patient Census: The patient census in sleep health grew by 4% year-over-year, while new starts in respiratory health increased by 4% and 5%, respectively, enhancing the company's market share and competitive position in the rapidly evolving health management sector.
- Successful Strategic Transformation: The company executed the largest capitated contract in the industry, onboarding the Mid-Atlantic cohort smoothly, marking a significant shift in its business model that is expected to provide strong support for future revenue growth.
- Optimistic Future Outlook: Management anticipates revenue growth of 6% to 8% in 2026, with significant contributions from new agreements, demonstrating the company's commitment to optimizing operations and capital allocation aimed at achieving long-term sustainable growth.
See More
AdaptHealth Reports Q4 Earnings Beat Expectations
- Earnings Highlights: AdaptHealth reported a Q4 EPS of -$0.76, which may not be comparable to the consensus of $0.34; however, its revenue of $846.2 million, down 1.2% year-over-year, beat expectations by $14.6 million, demonstrating resilience amid challenges.
- Annual Guidance: The company provided FY26 net revenue guidance of $3.44 billion to $3.51 billion, aligning with the consensus of $3.44 billion, indicating management's confidence in future growth despite market headwinds.
- Adjusted EBITDA Outlook: Expected adjusted EBITDA is projected between $680 million and $730 million, reflecting ongoing efforts in cost control and operational efficiency aimed at enhancing profitability.
- Free Cash Flow Forecast: The anticipated free cash flow range of $175 million to $225 million will support future investments and debt repayments, thereby strengthening the company's financial flexibility.
See More
AdaptHealth to Release Q4 and Full Year 2025 Financial Results
- Earnings Release Schedule: AdaptHealth is set to announce its fourth quarter and full year 2025 financial results before the market opens on February 24, 2026, which is expected to provide investors with critical financial data and updates on business activities.
- Teleconference Details: Management will host a teleconference at 8:30 a.m. ET to discuss the financial results, with investors able to participate by dialing (833) 316-2483 (Domestic) or (785) 838-9284 (International), ensuring transparency of information.
- Webcast Replay Availability: Following the live call, a replay will be available for six months on the company's website under the 'Investor Relations' section, facilitating access for investors who could not attend in real-time and enhancing engagement with stakeholders.
- Business Overview: AdaptHealth is a leading provider of patient-centered healthcare-at-home solutions, serving approximately 4.3 million patients through a network of about 640 locations across 47 states, offering services in four key segments: Sleep Health, Respiratory Health, Diabetes Health, and Wellness at Home, demonstrating significant market influence.
See More
